IDX 184

Drug Profile

IDX 184

Alternative Names: DX-184; IDX184

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Idenix Pharmaceuticals
  • Class Antivirals; Nucleotides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 19 Feb 2015 Idenix completes phase II trial in chronic Hepatitis C in USA and Puerto rico (NCT01371604)
  • 04 Feb 2013 Discontinued - Phase-I for Hepatitis C in USA (PO)
  • 04 Feb 2013 Discontinued - Phase-II for Hepatitis C in Puerto Rico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top